| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5942649 | Atherosclerosis | 2016 | 5 Pages |
Abstract
In the current study, we demonstrate reductions in LDL-C, HDL-C, triglycerides and Lp(a) during apheresis. Switching from LDL apheresis to evolocumab maintained the LDL-lowering effect but did not decrease HDL levels.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Knut Tore Lappegård, Terje Enebakk, Hilde Thunhaug, Anders Hovland,